Recon: FDA grants accelerated approval to Biogen ALS treatment; Novartis chief criticizes EU plans for compulsory licensing
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy